Long COVID, Major Depressive Disorder, Major Depressive Episode
Conditions
Keywords
PET, Long COVID, Major Depressive Disorder, Major Depressive Episode, Anhedonia, Dopamine Neuron Loss
Brief summary
The goal of this observational study focuses on understanding and addressing a subset of persistent neuropsychiatric symptoms occurring within 3 months after mild to moderate COVID-19 infection (COVID-DNP). COVID-DNP encompasses major depressive episodes (MDE) with or without additional neuropsychiatric symptoms.
Detailed description
Participants will undergo two positron emission tomography (PET) scans, one \[11C\]DTBZ scan (for vesicular monoamine transporter 2 (VMAT2) and one \[18F\]SDM8 scan (for synaptic vesicle glycoprotein 2A (SV2A)), as well as one magnetic resonance imaging (MRI) scan. The main question\[s\] it aims to answer are: 1. The investigators will determine if VMAT2 binding potential (VMAT2 BPND) is reduced in ventral striatum and dorsal putamen in COVID-DNP. 2. The investigators will determine if SV2A total distribution volume (SV2A VT) is reduced in ventral striatum and dorsal putamen in COVID-DNP
Interventions
OTHER[11C]DTBZ PET scan
One \[11C\]DTBZ scan for vesicular monoamine transporter 2 (VMAT2)
OTHER[18F]SDM8 PET scan
One \[18F\]SDM8 scan for synaptic vesicle glycoprotein 2A (SV2A)
OTHERMRI scan
One MRI scan
Sponsors
Centre for Addiction and Mental Health
Study design
Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
Yes
Inclusion criteria
* New onset MDE within 3 months after mild or moderate COVID-19, with MDE verified by the research version SCID for DSM 5. See "Positive COVID-19 diagnosis" listed after inclusion/
Exclusion criteria
for a description of how this is determined. * Age 18 to 75. * Good general physical health with no active medical conditions based on self-report (except migraine or PASC).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Vesicular Monoamine Transporter 2 Binding Potential (VAMT2 BPND) | within 3 to 4 weeks after initiation of screening | The investigators will determine if VMAT2 BPND is changed in ventral striatum and dorsal putamen in COVID-DNP. |
| Synaptic Vesicle Glycoprotein 2A Total Distribution Volume (SV2A VT) | within 3 to 4 weeks after initiation of screening | The investigators will determine if SV2A VT is changed in ventral striatum and dorsal putamen in COVID-DNP |
Countries
Canada
Contacts
CONTACTKarida Liu
CONTACTJeffrey Meyer
PRINCIPAL_INVESTIGATORJeffrey Meyer, M.D., PhD
Centre for Addiction and Mental Health
Outcome results
None listed